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Abstract Different studies have shown that -238 G[A polymorphism in promoter
region of tumor necrosis factor alpha (TNF-a) gene is associated with increased risk
of non-alcoholic fatty liver disease (NAFLD). The current study investigates the
association between metabolic parameters and nutritional intakes with -238 G[A
of TNF-a promoter gene polymorphism among the Iranian patients with NAFLD. In
this study, 75 patients with NAFLD and 76 individuals as control were enrolled.
Dietary intakes were assessed using a semi-quantitative food-frequency question-
naire. Body mass index and waist to hip ratio were calculated. Biochemical assays
were measured after 12 h fasting. -238 G[A Polymorphism of TNF-a gene was
determined by using sequencing method. We observed no significant difference in
frequency of different genotypes of this polymorphism between NAFLD and control
groups (P[ 0.05). Among biochemical parameters, TAC showed significant
decrease in NAFLD patients with GG genotype when compared to controls
(P = 0.001). The comparison of macro and micronutrient intakes between groups
according to genotypes showed no statistically significant difference (P[ 0.05).
Although the data were not statistically significant, further studies with larger
sample size are needed to determine the effect of dietary compounds in NAFLD.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is featured by abnormal accumulation of
droplet of triglycerides in the absence of significant alcohol consumption (Xu et al.
2013). NAFLD encompasses a spectrum that ranges from simple steatosis to non-
alcoholic steatohepatitis (NASH) (Weiß et al. 2014). It is strongly associated with
Type 2 Diabetes Mellitus (T2DM), central obesity, insulin resistance (IR), and
features of metabolic syndrome (Gaggini et al. 2013; Marchesini et al. 2003; Weiß
et al. 2014).
The prevalence of the NAFLD in developed countries is up to 30 % among the
general population, 50 % in patients with T2DM, 76 % in obese individuals, and
nearly 100 % in patients with morbid obesity (Adams et al. 2005; Browning et al.
2004).
Genetic polymorphism and nutrition intake are involved in NAFLD progression
as a multifactorial disease (Kalafati et al. 2014; Moore 2010). Dietary composition
can be a major factor to influence by altering the relative sources of hepatic fat
accumulation (Utzschneider and Kahn 2006). Therefore, knowledge on environ-
mental factors like diet and metabolic factors should be combined to achieve new
facts about genetic variety (Wang et al. 2012). Moreover, genetic variations are
associated with several factors such as reactive oxygen species, cytokines,
endotoxin receptors, and insulin resistance which are involved in susceptibility to
NAFLD (Zhou et al. 2010).
Insulin-resistant patients with NAFLD show decreased insulin sensitivity either
at the level of muscle or at the level of liver and adipose tissue (Bugianesi et al.
2005; Lomonaco et al. 2012). Insulin resistance is related to increase of free fatty
acids (FFAs) flux that causes increased triglyceride (TG) production, assembly, and
secretion of very low-density lipoprotein (VLDL) in hepatocytes. Fat accumulation
in liver is also linked with lipid peroxidation and oxidative stress (Gaggini et al.
2013). Oxidative stress phenomenon is induced by imbalance in the pro-oxidant/
antioxidant equilibrium; a condition that may influence a number of pathophysi-
ological events in the liver (Videla et al. 2004).
Tumor necrosis factor-alpha (TNF-a) is an important pro-inflammatory cytokine
and is associated with development forms of liver injury because of its possibility to
induce apoptosis, IR, and oxidative stress (Oliveira and Stefano 2015; Valenti et al.
2002; Wong et al. 2008). Previous studies in other countries have reported higher
prevalence of -238 TNF-a gene promoter polymorphism in NAFLD patients and
its association with high risk of IR (Oliveira and Stefano 2015; Wang et al. 2012).
The TNF-a gene is located on chromosome 6p21.3 in human which codes for a
157-amino acid polypeptide and processed from a 233-amino acid precursor
(Beutler and Cerami 1985). Immune cells in adipose tissue are a significant source
of TNF-a production (Vikram et al. 2011).
On the basis of relation between -238 G[A TNF-a polymorphisms with
NAFLD reported in other countries, in the current study, we aimed to evaluate the
association of -238 G[A polymorphism of TNF-a gene with NAFLD. Considering
the fact that there is no report about the relationship between -238 G[A TNF-a
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different genotypes with insulin resistance and oxidative stress parameters in
NAFLD patients, in this study we evaluated the relation between frequency of
different genotypes of this polymorphism with insulin resistance, oxidative stress
parameters, and nutritional intakes in NAFLD patients of North West of Iran.
Methods
The current case control study was carried out between 75 patients with NAFLD
and 76 healthy subjects. Patients were selected from the gastroenterology clinics of
Tabriz University of Medical Sciences, Tabriz, IRAN. Disease diagnosis was
confirmed by the physician based on the findings of ultrasonography (US). The
patients had simple steatosis (grades 1–2). Control group was composed of the
volunteers from university staff and acquired relatives of patients. They were
matched by age and gender with case group. Also US was done for healthy
volunteers to confirm the lack of NAFLD. Written informed consent was obtained
from all of participants.
Inclusion criteria were as follows: aged between 20 and 50 years and BMI
between 25 and 39.9 kg/m2. The exclusion criteria were as follows: other liver
diseases such as viral hepatitis, autoimmune or endocrine disorders, hemochro-
matosis, Wilson’s disease, pregnancy or lactation, alcohol consumption, using
hepatotoxic medications and being on weight loss diets for at least 3 months prior
participation in study.
Anthropometric Assessments
Subjects’ weight was measured with a calibrated scale (SECA, Hamburg, Germany)
to the nearest 0.1 kg, while they were in minimal clothing without shoes. Their
height was measured by non-stretchable measurement tape with the precision of
0.1 cm. Weight (kg) divided by height squared (m2) were calculated for body mass
index (BMI). Waist circumference (WC) was performed in standing position at the
level of the umbilicus, and hip circumference (HC) was measured at the maximum
circumference between the hip and the buttock with a non-elastic tape.
Biochemical Assessments
After an overnight fasting, 7 cc venous blood samples were obtained from subjects.
Approximately, 2 cc of the blood was transferred into tubes containing ethylene
diamine tetra acetic acid (EDTA) for genetic assays. Serum samples were obtained
from remaining blood for biochemical assays. Measuring of fasting serum glucose
(FSG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total
cholesterol (TC), TG, and high-density lipoprotein cholesterol (HDL-C) were
assessed by Abbott ALCYONTM 300 auto analyzer using commercial ELISA kits
(Pars-Azmoon, Tehran, Iran). Serum LDL-C was calculated by Friedewald formula
(Friedewald et al. 1972). Insulin resistance was estimated by the homeostasis model
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(HOMA-IR) by following equation: fasting serum insulin (lU/ml) 9 fasting
glucose (mg/dl)/405 (Tokushige et al. 2007).
Measuring of serum total antioxidant capacity (TAC) was performed by
colorimetric method using Randox Kit (Randox laboratories ltd., UK). Malondi-
aldehyde (MDA) levels were measured by thiobarbituric acid reactive substances
(TBARS) method. Samples were heated with 0.6 % thiobarbituric acid under acidic
condition; the colored product was extracted into n-butanol after cooling. The color
absorbance was measured at 530 nm. MDA standards were made with 1,1,3,3-
tetraethoxypropane. All of the biochemical assays were conducted by a trained lab
assistant who was blinded to group assignments.
Dietary Intakes
Dietary intakes were analyzed by semi-quantitative food-frequency questionnaire
(FFQ) adapted to the Iranian society (Mirmiran et al. 2009). The FFQ contained 168
food items with specified serving sizes usually consumed by Iranians. Study
subjects reported their average frequency intake of each food item in terms of the
number of specified serving sizes consumed per day/week/month/year, or never.
The reported frequency of food consumption and portion sizes were converted to a
daily intake.
DNA Extraction and Genotyping
Genomic DNA was isolated from the blood cells by salting out method (Miller et al.
1988). Our designed primers for evaluation of this polymorphism were 50-GGT
CCT ACA CAC AAA TCA GTC A-30 as forward primer and 50-GGA CAC ACA
AGC ATC AAG GA-30 as reverse primer. For doing polymerase chain reaction
(PCR), 1 ll of genomic DNA, 0.2 ll of Taq DNA polymerase, and 1 ll from each
primers were added to 22 ll of 19 PCR master-mix. PCR procedure included a
primary denaturation at 95 C for 5 min followed by 35 cycles of denaturation at
95 C for 1 min, annealing at 59 C for 1 min, extension at 70 C for 1 min, and a
final extension at 70 C for 5 min. Sequencing of PCR products was carried out
according to Sanger method using ABI 3730XL Capillary Sequencer. Sequencing
results were compared with the sequence of normal TNF-a gene obtained from
NCBI website: http://www.ncbi.nlm.nih.gov; also, sequence traces were assembled
using Chromas software (version 2.4). At position 238 of the TNF-a gene promotor
region, guanine substitutes to adenine and three different forms of genotypes of this
gene polymorphism are wild type (GG), heterozygote (GA), and homozygote (AA)
(Wang et al. 2012).
Statistical Analysis
All data analysis was performed using the SPSS software (Statistical Package for
the Social Sciences, SPSS Inc., Chicago, IL, USA). The normality of variables was
assessed by Kolmogorov–Smirnov test. Variables are expressed as mean ± stan-
dard deviation (SD) or numbers and percentages. The comparison of continuous
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variables between two groups was performed by 2-tailed independent sample t test.
Comparison of continuous variables between different TNF-a genotypes was
performed by analysis of covariance (ANCOVA) with adjustment for the
confounder effect of age and sex. Categorical variables were also compared using
the v2 test. Logistic regression analysis was used to assess the relationship between
anthropometric and biochemical variables with NAFLD genotypes adjusted for the
confounding role of sex and age. P value of less than 0.05 was considered to be
significant.
Results
The demographic features of the studied population are shown in Table 1. No
significant difference was observed in mean age and BMI between NAFLD and
healthy control groups. However, WC and waist to hip ratio (WHR) in NAFLD
patients were significantly higher when compared with control group (P\ 0.05).
Among biochemical variables in Table 2, serum HDL-C and LDL-C concentrations
were significantly lower and serum AST, ALT and triglyceride concentrations were
significantly higher in NAFLD patients compared to control group (P\ 0.05 and
P\ 0.01, respectively). HOMA-IR and MDA levels in patients with NAFLD and
control subjects did not have significant difference (P[ 0.05). Mean value of TAC
was significantly low in NAFLD patients compared to control group (P = 0.001).
The frequency distribution of different genotypes of -238 TNF-a polymorphism
in the study groups is presented in Table 3. We observed no significant difference in
GG and AG genotype between NAFLD and control groups (P[ 0.05). There was
no AA genotype in two studied groups.
The comparison of studied parameters according to different genotypes of -238
G/A polymorphism in TNF-a gene between NAFLD and control group is presented
in Tables 4 and 5. Waist circumference in NAFLD group was not significant in
comparison to control individuals according to genotypes (P[ 0,05); among the
Table 1 Demographic characteristics of study subjects
Variable NAFLD (n = 75) Control (n = 764) Mean difference (95 % CI) P*
Gender
Male n (%) 36 (48 %) 29 (38.2 %) – 0.252
Female n (%) 39 (52 %) 47 (61.8 %) –
Age (years) 40.65 (8.41) 38.87 (8.2) 1.78 (-0.89 to 4.46) 0.189
BMI (kg/m2) 31.78 (4.17) 31.38 (4.04) 0.40 (-0.92 to 1.72) 0.549
WC (cm) 103.12 (9.46) 100.14 (8.72) 2.98 (0.55 to 5.90) <0.046
WHR 0.92 (0.06) 0.89 (0.06) 0.02 (0.002 to 0.04) <0.031
Bold values indicate statistical significance (P\ 0.05)
BMI body mass index, WC waist circumference, WHR waist to hip ratio
* P value for gender based on Chi-square tests and P value for other variables based on 2-tailed
independent t test using equal variable. Variable’s data are presented based on mean (SD)
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biochemical parameters, TAC levels were significantly lower in NAFLD patients
with GG genotype in comparison to control subjects (P = 0.001). HOMA-IR and
MDA have shown no significant change in NAFLD patients with AG and GG
genotypes when compared with control group (P[ 0.05).
Statistical significant differences were not observed in dietary intakes between
patients and control subjects (P[ 0.05) (Table 6). The comparison of dietary
intakes between case and control groups according to different genotypes of -238
G/A TNF-a gene polymorphism is shown in Table 7. No statistical significant
difference was observed for nutrient intakes in studied groups with AG and GG
genotypes (P[ 0.05).
Table 2 Biochemical parameters of study subjects
Variable NAFLD (n = 75) Control (n = 76) Mean difference
(95 % CI)
P*
TC (mg/dl) 183.44 (36.91) 187.96 (28.89) -4.52 (-15.17 to 6.13) 0.403
HDL (mg/dl) 43.24 (11.4) 48.29 (11.6) -5.05 (-8.75 to -1.35) 0.008
LDL (mg/dl) 104.11 (34.62) 111.52 (26.43) -6.81 (-16.71 to 3.09) 0.030
FSG (mg/dl) 90.59 (11.24) 89.59 (9.93) 0.63 (-2.78 to 4.03) 0.717
ALT (IU/l) 49.96 (25.958) 26.84 (9.814) 23.12 (16.82 to 29.41) <0.001






MDA (nmol/ml) 2.82 ± 1.01 2.75 ± 1.03 -0.056 (-0.38 to 0.27) 0.734
TAC (lm/L) 1.45 ± 0.26 1.58 ± 0.28 0.12 (0.03 to 0.21) <0.005
Insulin (lU/ml) 19.10 (13.80–27.30) 17.70 (13.00–22.10) – 0.107
HOMA-IR 4.01 (3.21–6.21) 3.72 (2.71–5.33) – 0.139
Bold values indicate statistical significance (P\ 0.05)
TC total cholesterol, TG triglyceride, HDL high-density cholesterol, LDL low-density cholesterol, FSG
fasting serum glucose, ALT alanine amino transferase, AST aspartate amino transferase, MDA malondi-
aldehyde, TAC total antioxidants, HOMA-IR homeostasis model assessment insulin resistance
* P value for TG, insulin and HOMA-IR based on Mann–Whitney; otherwise based on independent t test
using equal variable. TG, insulin and HOMA-IR are presented based on median (P25–P75) and other
variable’s data are presented based on mean (SD)






P OR (95 % CI)
GG AG AA A
NAFLD (n = 75) 71 (94.7) 4 (5.3) 0 4 (1.4) 0.248 0.6 (0.20–2.05)
Control (n = 76) 68 (89.5) 8 (10.5) 0 8 (2.6)
 P value based on Chi-square tests
 Odds ratio (OR) for A allele based on logistic regression analysis (P[ 0.05)
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Table 4 The comparison of study anthropometric indices according to -238 G[A polymorphism of
TNF-a between study groups
Variable Genotype NAFLD (n = 75) Control (n = 76) Mean difference (95 % CI) P
BMI (kg/m2) AA – – – –
AG 31.40 (5.12) 32.21 (4.48) -1.87 (-8.75 to 4.99) 0.546
GG 31.81 (4.15) 31.28 (4.01) 0.68 (-0.63 to 2.00) 0.308
WHR AA – – – –
AG 0.86 (0.04) 0.92 (0.06) -0.04 (-0.10 to 0.01) 0.122
GG 0.92 (0.06) 0.89 (0.06) 0.01 (-0.01 to 0.03) 0.071
WC (cm) AA – – – –
AG 97.80 (2.18) 103.62 (5.75) -6.00 (-12.44 to 0.43) 0.064
GG 103.42 (9.63) 99.73 (8.95) 2.76 (-0.30 to 5.82) 0.076
BMI body mass index, WC waist circumference, WHR waist to hip ratio
 P value based on ANCOVA adjusted for age and gender. Variable’s data are presented based on mean
(SD)
Table 5 The comparison of HOMA-IR and oxidative stress parameters according to -238 G[A
polymorphism of TNF-a between study group
Variable Genotype NAFLD (n = 75) Control (n = 76) Mean difference
(95 % CI)
P
MDA (nmol/ml) AA – – – –
AG 2.45 (0.47) 2.46 (0.63) 0.78 (-0.96 to 0.80) 0.845
GG 2.84 (1.03) 2.78 (1.06) -0.005 (-0.33 to 0.34) 0.977
TAC (mg/dl) AA – – – –
AG 1.52 (0.31) 1.63 (0.21) -0.05 (-0.36 to 0.26) 0.698
GG 1.45 (0.26) 1.57 (0.28) -0.16 (-0.24 to -0.07) 0.001
FSG (mg/dl) AA – – – –
AG 84.50 (13.52) 91.62 (7.44) -19.07 (-40.17 to 2.022) 0.068
GG 90.92 (11.11) 89.76 (10.21) 0.59 (-3.00 to 4.19) 0.745
Insulin (lU/ml) AA – – – –
AG 18.45 (9.85–27.87) 19.00 (16.45–36.55) – 0.396
GG 19.10 (13.80–27.30) 17.65 (12.35–21.50) – 0.052
HOMA-IR AA – – – –
AG 3.62 (2.32–5.13) 4.33 (3.72–8.16) – 0.234
GG 4.01 (3.21–6.33) 3.62 (2.62–4.96) – 0.054
Bold value indicates statistical significance (P\ 0.05)
FSG fasting serum glucose, MDA malondialdehyde, TAC total antioxidants, HOMA-IR homeostasis
model assessment insulin resistance
 P value based on ANCOVA adjusted for age and gender. TG, insulin and HOMA-IR are presented
based on median (P25–P75) and other variable’s data are presented based on mean (SD)
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Table 6 Comparison of energy, macro and micronutrient intakes between study groups
Variable NAFLD (n = 75) Control (n = 76) Mean difference (95 % CI) P*
Calories (kcal) 2815.06 (536.35) 2794.93 (448.64) -20.13 (-179.29 to 139.03) 0.803
Protein (g/day) 93.88 (21.62) 88.88 (16.60) -4.99 (-11.20 to 1.20) 0.113
Carbohydrate (g/day) 437.38 (89.72) 438.49 (79.58) 1.10 (-26.18 to 28.39) 0.936
Total fat (g/day) 89.70 (27.03) 91.52 (24.35) 1.82 (-6.45 to 10.10) 0.664
Vitamin E (mg/day) 14.08 (5.60) 14.63 (4.11) 0.80 (-1.03 to 2.12) 0.496
Vitamin C (mg/day) 127.14 (66.09) 140.59 (64.18) 13.44 (-7.50 to 34.39) 0.207
Iron (mg/day) 23.37 (6.04) 22.86 (5.04) 0.90 (-2.30 to 1.27) 0.568
All data are presented as mean (SD)
* P value of variables based on 2-tailed independent t test using equal variable
Table 7 The comparison of energy, macro and micronutrient intakes according to -238 G[A poly-





Mean difference (95 %
CI)
P















Protein (g/days) AA – – – –
AG 101.09 (29.71) 102.27 (11.52) 5.10 (-18.47 to 28.66) 0.631
GG 93.47 (21.28) 87.31 (16.43) 4.11 (-1.41 to 9.62) 0.143
Carbohydrate
(g/days)
AA – – – –
AG 422.79 (82.36) 455.62 (65.73) -1.56 (-60.96 to 57.83) 0.953
GG 438.21 (90.59) 436.47 (81.23) -8.26 (-34.81 to 18.28) 0.539
Fat (g/days) AA – – – –
AG 97.70 (23.74) 104.88 (15.37) -5.61 (-34.97 to 23.74) 0.671
GG 89.25 (27.28) 89.95 (24.80) 0.28 (-8.58 to 9.15) 0.949
Vitamin E (mg/day) AA – – – –
AG 13.40 (4.76) 16.62 (3.89) -3.50 (-10.23 to 3.23) 0.264
GG 14.13 (5.66) 14.39 (4.10) -0.02 (-1.71 to 1.66) 0.978
Vitamin C (mg/day) AA – – – –
AG 96.91 (16.97) 110.24 (53.94) 0.97 (-67.27 to 69.22) 0.974
GG 128.85 (64.75) 144.16 (64.19) -15.55 (-37.96 to 6.86) 0.172
Iron (mg/d) AA – – – –
AG 21.89 (6.82) 22.03 (4.51) -2.36 (-8.96 to 4.23) 0.432
GG 23.46 (6.04) 22.48 (4.99) 0.33 (-1.36 to 2.03) 0.695
 P value for analysis of co variance (ANCOVA) adjusted for confounding effects of age and gender
All data are presented as mean (SD)
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Discussion
In the current case–control study, we evaluated different genotypes frequency of
-238 G/A polymorphism in TNF-a gene among the NAFLD patients. Generally
speaking, differences in genotype distribution in various population can be
explained by racial/ethnic differences (Mcgraw and Waller 2012).
Distribution of different genotypes and allele frequency of our studied
polymorphism among the Iranian population had complete concordance with
Japanese population. In this regard, Tokushige et al. (2007) reported no significant
difference in genotypes and allele frequency of this polymorphism among 102
Japanese patients with fatty liver in comparison to healthy group. In their study, the
same as our research, there were no AA genotypes among the studied samples, and
they also showed no significant difference in GG and AG genotype frequency
between NAFLD and control subjects. However, in other populations, some studies
have been reported higher frequency of AG genotype in case group compared to
control ones (Valenti et al. 2002; Wong et al. 2008).
Central obesity and insulin resistance are well characterized to be associated with
intra-abdominal fat accumulation which has been positively correlated with liver fat
(Utzschneider and Kahn 2006). Waist circumference as a marker of central obesity
has shown higher significant difference in NAFLD patients than healthy subjects.
However, WC and WHR did not associate with different genotypes of TNF-a gene
in patients compared to control. In agreement with our study, Hedayati et al. (2012)
have reported no association between obesity and different genotypes of the
mentioned polymorphism.
About the serum insulin and HOMA-IR, we did not observe significant
association with different genotypes in our studied groups; in the line of our
results, Tokushige et al. (2007) have reported no association between HOMA-IR
with AG and GG genotypes in NAFLD patients; however, their control study group
was not obese. On the other hand, Day et al. (1998) reported high A allele frequency
in 123 non-diabetes relatives with lower HOMA-IR compared to control group. The
possible explanation is that -238 TNF-a gene promoter polymorphism may be
affected by population stratification and other relevant genetic variants (Day et al.
1998).
Concentration of Malondialdehyde (MDA), one of the most frequently used
biomarker to indicate lipid peroxidation, was not associated with different
genotypes of this polymorphism in our studied groups. On the other hand, among
our samples, NAFLD patients with GG or normal genotype showed low TAC in
comparison to control. These findings were in agreement with a study by Ostad
Rahimi et al. (2011), where they showed significant low-serum TAC level in
NAFLD patients. Other studies by Videla et al. (2004) and Yesilova et al. (2005)
have reported similar results; however unlike our study, no association between
biomarkers of oxidative stress and gene polymorphisms has been evaluated in their
studies. The possible mechanism of the development of higher oxidative stress
status in patients with NAFLD can be related to serum levels of the Kupffer cell and
stellate cell-derived cytokines such as TNF-a (Videla et al. 2004).
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In our study, the comparison of macro and micronutrient intake did not show any
statistically significant differences between subjects. Similar to our findings, Zelber-
Sagi et al. (2007) study showed no statistically significant differences in nutrients
intake between NAFLD and normal liver groups.
In our study, we did not achieve significant differences in nutrients intake
according to genotypes of this polymorphism. These associations are needed to be
conducted in larger and best possible prospective studies designed for confirming
the obvious dietary intake recommendations to prevent of NAFLD progression.
Conclusion
In conclusion, TNF-a promoter gene polymorphism at position -238 did not show
to be associated with NAFLD among the North West Iranian population. Our results
showed that among the metabolic parameters, TAC was significantly low in patients
with GG genotype. Also, not achieving significant results in some findings might be
attributed to relatively small sample size. Further studies with larger sample size and
interventional designs are needed to determine the effect of dietary compounds in
non-alcoholic fatty liver disease.
Acknowledgments We appreciate all of the participants in the current study. We also thank Nutrition
Research Center of Tabriz University of Medical Sciences and Cellular and Molecular Research Center of
Qazvin University of Medical Science for providing laboratory facilities.
Funding This research was supported by a grant from cellular and molecular research center of Qazvin
University of Medical Sciences.
Compliance with Ethical Standards
Conflict of interest The authors declare that there is no conflict of interest.
References
Adams LA, Lymp JF, Sauver JS, Sanderson SO, Lindor KD, Feldstein A et al (2005) The natural history
of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:113–121
Beutler B, Cerami A (1985) Cachectin and tumour necrosis factor as two sides of the same biological
coin. Nature 320:584–588
Browning JD, Szczepaniak LS, Dobbins R (2004) Prevalence of hepatic steatosis in an urban population
in the United States: impact of ethnicity. Hepatology 40:1387–1395
Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S et al (2005) Insulin resistance in
non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia
48:634–642
Day C, Grove J, Daly AK, Stewart MW, Avery PJ, Walker M (1998) Tumour necrosis factor-alpha gene
promoter polymorphism and decreased insulin resistance. Diabetologia 41:430–434
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density
lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem
18:499–502
694 Biochem Genet (2016) 54:685–695
123
Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A (2013) Non-alcoholic fatty
liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and
coronary heart disease. Nutrients 5:1544–1560
Hedayati M, Sharifi K, Rostami F, Daneshpour M, Yeganeh M, Azizi F (2012) Association between TNF-
a promoter G-308A and G-238A polymorphisms and obesity. Mol bio rep 39:825–829
Kalafati I, Borsa D, Dedoussis GVZ (2014) The genetics of nonalcoholic fatty liver disease: role of diet as
a modifying factor. Curr Nutr Rep 3:223–232
Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C et al (2012) Effect of adipose tissue
insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic
fatty liver disease. Hepatology 55:1389–1397
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al (2003) Nonalcoholic fatty
liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923
McGraw J, Waller D (2012) Cytochrome P450 variations in different ethnic populations. Expert Opin
Drug Metab Toxicol 8:371–382
Miller S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from nucleated
cells. Nucleic Acid Res 16:1215
Mirmiran P, Hosseini Esfahani F, Mehrabi Y, Hedayati M, Azizi F (2009) Reliability and relative validity
of an FFQ for nutrients in the Tehran lipid and glucose study. Public Health Nutr 13:654–662
Moore J (2010) Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic
syndrome. Proc Nutr Soc 69:211–220
Oliveira C, Stefano J (2015) Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis
(NASH): a mini review. Clin Res Hepatol Gastroenterol 39:S35–S40
Ostad Rahimi A, Mahdavi R, Somi MH, Tarzemani MK (2011) Oxidative stress-related parameters and
antioxidant status in non-alcoholic fatty liver disease patients. IJEM 12:493–499
Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K (2007) Influence
of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol
46:1104–1110
Utzschneider K, Kahn S (2006) The role of insulin resistance in nonalcoholic fatty liver disease. J Clin
Endocrinol Metab 91:4753–4761
Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E et al (2002) Tumor necrosis
factor a promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease.
Gastroenterology 122:274–280
Videla L, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L et al (2004) Oxidative stress-related
parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci 106:261–268
Vikram N, Bhatt S, Bhushan B, Luthra K, Misra A, Poddar PK et al (2011) Associations of -308G/A
polymorphism of tumor necrosis factor (TNF)-a gene and serum TNF-a levels with measures of
obesity, intra-abdominal and subcutaneous abdominal fat, subclinical inflammation and insulin
resistance in Asian Indians in North India. Dis Markers 31:39–46
Wang J, Feng Z, Li Y, Li Q, Tao XY (2012) Association of tumor necrosis factor-a gene promoter
polymorphism at sites-308 and-238 with non-alcoholic fatty liver disease: a meta-analysis.
J Gastroenterol Hepatol 27:670–676
Weiß J, Rau M, Geier A (2014) Non-alcoholic fatty liver disease: epidemiology, clinical course,
investigation, and treatment. Dtsch Arzteblatt Int 111:447–452
Wong V, Wong G, Tsang SW, Hui AY, Chan AW, Choi PC et al (2008) Genetic polymorphisms of
adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people.
J Gastroenterol Hepatol 23:914–921
Xu Y, Liang L, Wang CL, Fu JF, Liu PN, Lv LQ et al (2013) Association between UCP3 gene
polymorphisms and nonalcoholic fatty liver disease in Chinese children. World J Gastroenterol
19:5897–5903
Yesilova Z, Yaman H, Oktenli C, OzcanA UA, Cakir E et al (2005) Systemic markers of lipid
peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol
100:850–855
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z et al (2007) Long term
nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based
study. J Hepatol 47:711–717
Zhou Y, Li Y, Nie Y, Yang H, Zhan Q, Huang J et al (2010) Influence of polygenetic polymorphisms on
the susceptibility to non-alcoholic fatty liver disease of Chinese people. J Gastroenterol Hepatol
25:772–777
Biochem Genet (2016) 54:685–695 695
123
